February 2026 Health Care Technology Standards: Key Updates in Diagnostics, Devices, and Tissue Care

Health care technology professionals have new guidance to consider with the release of five essential international standards in February 2026. Addressing areas from molecular diagnostics and traditional medicine to assistive products, incontinence management, and ophthalmic devices, these updates strengthen best practices for quality, safety, and compliance. This article, the first in a four-part series, breaks down the scope, requirements, and technical implications of the latest standards for proactive industry leaders.

Overview / Introduction

Health care technology is a rapidly advancing sector where rigorous international standards play a vital role. From clinical laboratories and product manufacturers to regulatory agencies and medical researchers, professionals rely on these specifications to ensure product performance, patient safety, and legal compliance. The newly published standards in February 2026 focus on diverse yet interconnected domains: molecular in vitro diagnostics, herbal medicine quality, incontinence product evaluation, assistive products for tissue integrity, and intraocular lens labeling.

This comprehensive guide will:

• Examine the updated requirements and recommendations for each standard
• Explain their industry relevance and link to best practices
• Provide actionable information for compliance and implementation

Detailed Standards Coverage

EN ISO 18704:2026 - Molecular in Vitro Diagnostic Examinations: Pre-examination of Cell-Free DNA in Body Fluids

Molecular in vitro diagnostic examinations – Requirements and recommendations for pre-examination processes for urine and other body fluids – Isolated cell-free DNA (ISO 18704:2026)

EN ISO 18704:2026 sets out requirements and recommendations for the entire pre-examination phase when isolating cell-free DNA (cfDNA) from human body fluids other than blood—such as urine, pleural effusions, ascites, cerebrospinal fluid (CSF), and saliva. The standard provides a structured workflow covering specimen collection, handling, storage, transport, processing, and documentation, recognizing the delicate nature of cfDNA and its value in diagnostic and research settings.

Scope and requirements include:

• Specimen collection using validated devices with or without cfDNA stabilizers
• Handling protocols to prevent DNA degradation or contamination
• Transport and storage requirements custom-fitted to the sample matrix and downstream analysis
• Documentation standards for tracking and traceability
• cfDNA isolation methods using either commercial kits or lab-developed procedures
• Quality and quantity assessments of isolated cfDNA
• Excludes guidance for nucleated cell analysis and microbiome DNA preservation—these are outside its remit

Targeted toward medical laboratories, in vitro diagnostic exam developers and manufacturers, biobanks, and research institutions, the standard is engineered for harmonization with ISO 15189 and ISO 13485 quality management requirements.

Key highlights:

• Comprehensive coverage of pre-analytical variables in cfDNA testing for non-blood body fluids
• Detailed procedures minimize DNA degradation and ensure specimen traceability
• Supports regulatory and research compliance in personalized medicine and clinical genomics

Access the full standard:View EN ISO 18704:2026 on iTeh Standards

ISO 21590:2026 - Crocus Sativus Stigma Quality and Safety for Traditional Chinese Medicine

Traditional Chinese medicine — Crocus sativus stigma

ISO 21590:2026 delivers global quality and safety requirements for Crocus sativus stigma (saffron), widely used in herbal medicine and traded across borders. The standard responds to disparate national regulations by providing harmonized specifications for the morphology, chemical composition, purity, and labeling of Crocus sativus stigma intended for use in Chinese materia medica and decoction pieces.

Key requirements include:

• General and morphological characteristics (appearance, color, shape)
• Microscopic and thin-layer chromatographic identification
• Permissible moisture and total ash contents
• Maximum allowable levels for heavy metals and pesticide residues
• Restrictions on artificial colorants and requirements for marker compound content (e.g., crocin-I, crocin-II)
• Clear labeling, packaging, and storage recommendations

This standard is crucial for herbal product manufacturers, exporters, importers, quality managers, and pharmacopoeia authorities ensuring global market access for Crocus sativus. It also creates a unified reference for regulatory compliance and assures practitioners and consumers of product safety.

Key highlights:

• Unified testing and identification methods for Crocus sativus stigma
• Benchmark limits for contaminants (heavy metals, pesticides, colorants)
• Foundational guidance for labeling and traceability in international trade

Access the full standard:View ISO 21590:2026 on iTeh Standards

ISO 15621:2026 - General Guidelines on Evaluation of Absorbent Incontinence Products

Absorbent incontinence products for urine, faeces, or both — General guidelines on evaluation

Incontinence products are essential for quality of life in patients of all ages. ISO 15621:2026 offers a structured methodology for evaluating absorbent incontinence products addressing both user experience and product performance. The updated standard covers products for urine, faeces, or both and is applicable to manufacturers, purchasing bodies, caregivers, and care facilities.

Key requirements include:

• User-related considerations: independence/assistance needed, quality of life, activity levels, comfort, and fit
• Product-related criteria: absorbency, leakage control, odor management, skin health, ergonomics, discretion, safety, cost, and sustainability
• Usage factors: ease of handling, needs of caregivers, product information, and disposable management
• Descriptions of evaluation methods, including laboratory testing, user trials, and combined approaches
• Sample size recommendations and data interpretation guidance

The standard ensures that incontinence products are evaluated in real-world use, supporting better procurement decisions, user well-being, and cost management.

Key highlights:

• Comprehensive framework for incontinence product assessment considering clinical and user-centered factors
• Aligned terminology and methods with supporting ISO standards
• End-user focus to optimize independence, dignity, and comfort

Access the full standard:View ISO 15621:2026 on iTeh Standards

EN ISO 20342-4:2026 - Durability Test Methods for Assistive Products for Tissue Integrity (APTI)

Assistive products for tissue integrity when lying down – Part 4: Test methods for durability (ISO 20342-4:2026)

EN ISO 20342-4:2026 addresses the crucial need for standardized durability testing of assistive products used to maintain tissue integrity in patients who are lying down—such as specialized mattresses and overlays. The standard supplements ISO 20342-1 by detailing test methods for both reactive and active aids, excluding single-use products.

Key requirements and technical provisions include:

• Durability test protocols simulating multi-cycle usage on articulated platforms
• Methods for assessing resistance to user movement and repositioning
• Evaluation procedures for environmental resilience (storage and operational conditions)
• Criteria for reporting test results, ensuring traceable and reproducible assessments

Intended for manufacturers, procurement specialists, clinicians, and certifying bodies, the standard promotes quality assurance, informs purchasing, and supports product development. It clarifies which tests apply to specific product types based on their design and intended environment.

Key highlights:

• Consistent, reproducible durability tests for mattresses and overlays used by immobile or at-risk patients
• Comparative framework to differentiate product life expectancy and reliability
• Documentation protocols for robust quality management and procurement

Access the full standard:View EN ISO 20342-4:2026 on iTeh Standards

ISO 11979-4:2026 - Labelling and Information for Intraocular Lenses

Ophthalmic implants — Intraocular lenses — Part 4: Labelling and information

ISO 11979-4:2026 specifies new and harmonized labeling requirements for intraocular lenses (IOLs), designed to bring greater clarity and consistency for eye surgeons, regulatory bodies, and manufacturers. The standard lays out the minimal information required on product packaging and patient information, facilitating global compliance while allowing accommodation for national regulations.

Areas covered include:

• Mandatory labeling requirements for IOL packaging, including manufacturer details, product identification, and expiration dates
• Inclusion of instructions for use and self-adhesive labels for protective wrapping
• Guidance on patient information materials, such as patient leaflets and implant cards
• Use of standardized symbols in compliance with ISO 20417 and related standards
• Updates reflecting changes in clinical requirements and types of IOLs (e.g., supplementary or special visual IOLs)

This document underpins safe use, traceability, and transparency across the IOL supply chain, from manufacturer to surgeon to patient.

Key highlights:

• Harmonized global labeling, minimizing interpretive errors and supporting regulatory approval
• Alignment with evolving clinical practices for ophthalmic implants
• Enhanced traceability and patient safety via robust documentation and labeling

Access the full standard:View ISO 11979-4:2026 on iTeh Standards

Industry Impact & Compliance

The publication of these five standards brings wide-ranging effects across the health care technology field.

For businesses and organizations:

• Improved risk management through clearly defined, up-to-date requirements
• Simplified procurement and product evaluation with harmonized specifications
• Enhanced capability to secure regulatory approvals in multiple jurisdictions

Compliance considerations:

• Organizations must update quality management systems to reflect new requirements (especially for cfDNA sample management and IOL labeling)
• Procurement teams and manufacturers should review documentation and process controls to demonstrate adherence to updated testing, labeling, or ingredient standards
• Laboratories and biobanks need to train staff on new workflows for sample handling and record-keeping

Benefits of adoption:

• Higher product quality, performance, and patient safety
• Streamlined audits and certification processes
• Improved international trade prospects, thanks to harmonized quality and labeling practices

Risks of non-compliance:

• Regulatory non-acceptance, product recalls, or exclusion from major markets
• Potential for misdiagnosis or patient harm due to improper handling, labeling, or testing
• Loss of trust among clients, clinicians, or patients

Technical Insights

While each standard covers a specific area, several technical themes emerge:

• Traceability and Documentation: Essential for cfDNA processes, Crocus sativus sourcing, incontinence product testing, and device labeling.
• User-Centered Design and Safety: Whether ensuring mattresses and overlays maintain durability for tissue integrity, or that incontinence products meet real-world needs, standards always prioritize user welfare.
• Testing and Certification: All covered standards build on existing testing protocols, with guidance tailored to product type and application. Manufacturers and laboratories should maintain validated measurement tools, train personnel, and keep up-to-date testing records.
• Harmonization and Interoperability: By aligning terminology and methods (e.g., with references to ISO 15189, 13485, 20417, 22748), these standards support a unified approach across the industry.

Best practices for implementation:

1. Conduct gap analyses comparing current processes to new requirements.
2. Update internal SOPs, training, and documentation.
3. Engage with testing laboratories or certification bodies as needed.
4. Communicate changes upstream (manufacturers) and downstream (clinicians, end-users) to ensure a smooth transition.

Conclusion / Next Steps

The February 2026 set of standards marks a significant advancement in health care technology, bringing strengthened quality, safety, and compliance frameworks across diagnostics, herbal medicine, incontinence management, tissue integrity, and ophthalmic devices.

Key takeaways:

• Harmonized global guidance improves quality and regulatory acceptance
• User and patient safety are at the forefront of every specification
• Documentation, testing, and labeling requirements are more rigorous than ever

Recommendations:

• Organizations should proactively review these standards, update quality management systems, and engage relevant stakeholders.
• Quality managers and compliance officers must plan for implementation and training well ahead of regulatory deadlines.
• Procurement specialists and manufacturers should consult the full texts of all standards to understand nuanced requirements.

Explore the full collection of health care technology standards and stay ahead of regulatory trends at iTeh Standards.

Stay tuned for Part 2 of our February 2026 Health Care Technology Standards series, which will cover additional key updates for the industry!